Medicare Enrolled

Dr. David Amran, M.D.

Allergy & Immunology · Sugar Land, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Speaking/Promotional
4820 SWEETWATER BLVD, Sugar Land, TX 77479
2814944600
In practice since 2005 (20 years)
NPI: 1841294261 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Amran from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Amran? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Amran

Dr. David Amran is an allergy & immunology in Sugar Land, TX, with 20 years in practice. Based on federal Medicare data, Dr. Amran performed 105,651 Medicare services across 2,125 unique beneficiaries.

Between the years covered by Open Payments, Dr. Amran received a total of $97,011 from 49 pharmaceutical and/or device companies across 936 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in allergy & immunology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Amran is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice▲ Top 1% volume in TX$ $97,011 industry payments

Medicare Practice Summary

Medicare Utilization ↗
105,651
Medicare services
Top 1% in TX for allergy & immunology
2,125
Unique beneficiaries
$26
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~5,283 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Omalizumab injection (Xolair) for asthma/allergy34,577$30$42
Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg24,923$38$115
Injection, mepolizumab, 1 mg20,201$22$57
Allergy immunotherapy preparation7,870$11$15
Allergy skin test6,976$3$15
Allergy injection therapy, multiple injections3,175$8$32
Drug injection, under skin or into muscle1,488$11$150
Test for allergy using allergenic extract injected into skin1,338$6$13
Infusion into a vein for therapy, prevention, or diagnosis, each additional hour1,100$16$100
Office visit, established patient (20-29 min)1,014$66$135
Test to measure expiratory airflow and volume changes before and after medication administration601$29$175
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less504$49$200
Office visit, established patient (10-19 min)318$42$82
Test to measure expiratory airflow and volume295$20$110
Test to measure the level of nitric oxide gas269$14$32
Inhalation treatment for airway obstruction or sputum production157$7$50
Office visit, established patient (30-39 min)154$92$194
Blood draw (venipuncture)101$8$15
Test to measure resistance of the airways and lungs to differing frequencies80$29$325
Test to determine lung volumes using sensors79$41$270
Test to examine how well the lungs exchange gases78$43$120
Flu vaccine administration68$29$30
Flu vaccine, high-dose67$68$70
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle43$45$150
Detection test by immunoassay with direct visual observation for influenza virus40$16$30
New patient office visit (45-59 min)30$121$250
Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mg24$0$10
Detection test by immunoassay with direct visual observation for severe acute respiratory syndrome coronavirus 2 (covid-19)21$41$60
Pneumonia vaccine administration19$29$30
New patient office visit, complex (60-74 min)15$163$393
Pneumococcal vaccine, 23-valent14$131$150
New patient office visit (30-44 min)12$80$188
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.5% high complexity
79.9% medium
18.6% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$97,011
Total received (2018-2024)
Avg $13,859/year across 7 years
Top 6% in TX for allergy & immunology
49
Companies
936
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$82,977 (85.5%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$14,034 (14.5%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$11,188
2023
$11,591
2022
$18,824
2021
$34,344
2020
$11,733
2019
$5,907
2018
$3,424

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
GlaxoSmithKline, LLC.
$69,307
AstraZeneca Pharmaceuticals LP
$7,279
Novartis Pharmaceuticals Corporation
$6,562
Regeneron Healthcare Solutions, Inc.
$3,598
GENZYME CORPORATION
$2,404
PFIZER INC.
$663
Takeda Pharmaceuticals U.S.A., Inc.
$538
Genentech USA, Inc.
$522
kaleo, Inc.
$516
Amgen Inc.
$471
ABBVIE INC.
$442
Grifols USA, LLC
$440
Teva Pharmaceuticals USA, Inc.
$416
Optinose US, Inc.
$416
Pharming Healthcare, Inc.
$402
LEO Pharma Inc.
$354
SANOFI-AVENTIS U.S. LLC
$266
OptiNose US, Inc.
$261
Octapharma USA, Inc.
$217
Incyte Corporation
$216
Boehringer Ingelheim Pharmaceuticals, Inc.
$203
AbbVie Inc.
$189
CSL Behring
$145
Mylan Specialty L.P.
$142
Blueprint Medicines Corporation
$138
Shire North American Group Inc
$119
SANOFI PASTEUR INC.
$111
Kaleo, Inc.
$68
ALK-Abello, Inc
$66
HOSPIRA, INC.
$61
TerSera Therapeutics LLC
$50
AbbVie, Inc.
$44
Hikma Pharmaceuticals USA
$40
BioCryst US Sales Co., LLC
$37
ADMA BioManufacturing LLC
$31
Galderma Laboratories, L.P.
$30
Cycle Pharmaceuticals Inc
$26
Pulmonx Corporation
$25
Xeris Pharmaceuticals, Inc.
$21
X4 Pharmaceuticals, Inc.
$20
Merck Sharp & Dohme LLC
$20
Horizon Pharma plc
$20
Horizon Therapeutics plc
$19
Philips Electronics North America Corporation
$19
Phadia US Inc.
$17
Insmed, Inc.
$15
Lilly USA, LLC
$15
Aytu BioPharma, Inc.
$14
Aytu Bioscience, Inc
$14
Top 3 companies account for 85.7% of total payments
Associated products mentioned in payments ›
ACTIMMUNE · ADACEL · ADBRY · AIRSUPRA · AKLIEF · AREXVY · AUVI-Q · AYVAKIT · Aciphex · AirDuo Digihaler · Arikayce · Auvi-Q · BREO · BREZTRI · BREZTRI AEROSPHERE · CHARTIS CATHETER · CIBINQO · CINQAIR · CUVITRU · DUPIXENT · DUPIXENT DUPILUMAB INJECTION · Dymista · EBGLYSS · EOHILIA · EUCRISA · EVUSHELD · FASENRA · FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE · FLUZONE HIGH-DOSE · FLUZONE QUADRIVALENT · GVOKE HYPOPEN · Gamunex-C · HYQVIA · Haegarda · Hizentra · ImmunoCAP · Karbinal · NO PRODUCT DISCUSSED · NUCALA · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OPZELURA · ORLADEYO · Odactra · PANZYGA · PREVNAR 20 · ProAir Digihaler · QVAR · Quzyttir · RINVOQ · RUCONEST · Ryaltris · SHINGRIX · SPIRIVA · SPIRIVA RESPIMAT · STIOLTO RESPIMAT · SYMBICORT · Sajazir · Skyrizi · TAKHZYRO · TEZSPIRE · TRELEGY ELLIPTA · XOLAIR · XOLREMDI · Xembify · Xhance · Xofluza · Xolair · YUPELRI · Yupelri · inCourage
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (86%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in allergy & immunology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 6% for allergy & immunology in TX.

Equivalent to $92 per 100 Medicare services performed
Looking for a allergy & immunology in Sugar Land?
Compare allergy & immunologys in the Sugar Land area by procedure volume, costs, and industry payment transparency.
Browse allergy & immunologys nearby

Geographic Context

Allergy & Immunologys within 10 mi
50
Per 100K population
5.8
County median income
$113,409
Nearest hospital
HOUSTON METHODIST SUGARLAND HOSPITAL
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Amran is a mixed practice specialist, with above-average Medicare volume (top 1% in TX), and high industry engagement (speaking/promotional, top 6%), with 20 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Amran experienced with omalizumab injection (xolair) for asthma/allergy?
Based on Medicare claims data, Dr. Amran performed 34,577 omalizumab injection (xolair) for asthma/allergy services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Amran receive payments from pharmaceutical companies?
Yes. Dr. Amran received a total of $97,011 from 49 companies across 936 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Amran's costs compare to other allergy & immunologys in Sugar Land?
Dr. Amran's average Medicare payment per service is $26. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Amran) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →